Despite robust results, pharma ETFs have been trending downward in a month.

Several companies sit at the forefront of developing a coronavirus vaccine. Gain exposure to each using the following three ETFs.

Robust results led to solid trading in pharma ETFs in a month.

Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.

Pharmaceuticals stocks and ETFs, including the VanEck Vectors Pharmaceutical ETF (PPH) , rallied Friday after Senate Majority Leader Mitch McConnell (R-KY) said a House effort to lower drug prices led by Speaker Nancy Pelosi (D-CA) will not be considered by the Senate. “Senate committees have passed their own versions but the GOP is not united on the issue. Deep-pocketed drug makers are spending millions on lobbyists to ensure that there will be no substantial constraints on prices,” according to Seeking Alpha.

AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.

Pharmaceutical exchange-traded funds (ETFs) offer investors access to a basket of U.S.-based and foreign stocks of drug manufacturers and related companies in a single investment. These companies discover, develop, and produce medications used to cure disease, vaccinate, or alleviate symptoms of illness.

These sectors are directly related to the outbreak of Coronavirus in China in a positive or negative way,putting the spotlight on these ETFs and stocks.

Sector ETF report for PPH

Institutional investors and hedge funds have shifted away from technology names as the U.S.-China trade war extends and picked up battered healthcare names. Retail investors can also gain exposure to the ...

Pharma sector wins in October, making these ETFs and stocks winners.

Pharmaceutical sector-specific exchange traded funds showed mixed results Tuesday after AbbVie (NYSE: ABBV) agreed to acquire Allergan (NYSE: AGN) for $63 billion. Among the largest pharma-specific ETFs, ...

The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

Strong results led to solid trading in pharma ETFs over the past week.